SHR-2173

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Systemic Lupus ErythematosusLupus NephritisImmune ThrombocytopeniaIga NephropathyMembranous Nephropathy

328 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

1

Eptanemab

UCB

Phase 3

122

Medrol

Pfizer

Phase 3

53

Olumiant

Eli Lilly

Phase 3

44

Cytoxan

BBaxter Healthcare Corporation

Phase 3

115

Intrarosa

Alnylam Pharmaceuticals

Phase 3

16

Rayos

RRoxane Laboratories

Phase 3

67

Depo-Provera

Eli Lilly

Phase 3

—8

Cellcept

Novartis

Phase 3

—9

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

210

Rapamune

PPrism Pharmaceuticals

Phase 3

1Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus2 trials

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus

Completed·Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 1·NCT06955598·30 enrolled

A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus

Not yet recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 2·NCT07299422·248 enrolled

Tics1 trial

Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects

Completed·Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 1·NCT06995001·35 enrolled

Lupus Nephritis1 trial

A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis

Recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 2·NCT07229742·51 enrolled

Immune Thrombocytopenia1 trial

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

Recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 1·NCT07206758·10 enrolled

Membranous Nephropathy1 trial

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

Recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 2·NCT07289763·75 enrolled

1 more indication

IgA Nephropathy1 trial

A Study of SHR-2173 in Participants With Primary IgA Nephropathy

Not yet recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 2·NCT07354932·84 enrolled

Details

Drug Info

Related News